Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control

Our findings demonstrated that the addition of dapagliflozin to an existing drug regimen consisting of three different OHAs in patients exhibiting inadequate blood glucose control could be alternate treatment modality in T2D who hesitate to initiate insulin therapy.